Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Part A RECCE327 topical gel in ABSSSI and diabetic foot infections
ACTRN12624000973516Phase 2Recruiting
- Sponsor
- Recce Pharmaceuticals Ltd
- Start
- Aug 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RECCE 327 in acute bacterial skin and skin structure infection (ABSSSI) and diabetic foot infection (DFI), sponsored by Recce Pharmaceuticals Ltd. Primary endpoints: Systemic bioavailability of single and multiple doses of RECCE327 topical gel, Absorption of RECCE327 topical gel and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
RECCE 327
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)diabetic foot infection (DFI)
Beyond the preview
Go deeper on ACTRN12624000973516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000973516.